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Omar Faiz, Julian Teare, Richard J Lilford, Dion Morton, Jane Wardle, Wendy Atkin, for the SIGGAR investigators*
Summary
Background Barium enema (BE) is widely available for diagnosis of colorectal cancer despite concerns about its 
accuracy and acceptability. Computed tomographic colonography (CTC) might be a more sensitive and acceptable 
alternative. We aimed to compare CTC and BE for diagnosis of colorectal cancer or large polyps in symptomatic 
patients in clinical practice.
Methods This pragmatic multicentre randomised trial recruited patients with symptoms suggestive of colorectal 
cancer from 21 UK hospitals. Eligible patients were aged 55 years or older and regarded by their referring clinician as 
suitable for radiological investigation of the colon. Patients were randomly assigned (2:1) to BE or CTC by computer-
generated random numbers, in blocks of six, stratiﬁ ed by trial centre and sex. We analysed the primary outcome—
diagnosis of colorectal cancer or large (≥10 mm) polyps—by intention to treat. The trial is an International Standard 
Randomised Controlled Trial, number 95152621.
Findings 3838 patients were randomly assigned to receive either BE (n=2553) or CTC (n=1285). 34 patients withdrew 
consent, leaving for analysis 2527 assigned to BE and 1277 assigned to CTC. The detection rate of colorectal cancer or 
large polyps was signiﬁ cantly higher in patients assigned to CTC than in those assigned to BE (93 [7·3%] of 1277 vs 
141 [5·6%] of 2527, relative risk 1·31, 95% CI 1·01–1·68; p=0·0390). CTC missed three of 45 colorectal cancers and 
BE missed 12 of 85. The rate of additional colonic investigation was higher after CTC than after BE (283 [23·5%] of 
1206 CTC patients had additional investigation vs 422 [18·3%] of 2300 BE patients; p=0·0003), due mainly to a higher 
polyp detection rate. Serious adverse events were rare.
Interpretation CTC is a more sensitive test than BE. Our results suggest that CTC should be the preferred radiological 
test for patients with symptoms suggestive of colorectal cancer.
Funding NIHR Health Technology Assessment Programme, NIHR Biomedical Research Centres funding scheme, 
Cancer Research UK, EPSRC Multidisciplinary Assessment of Technology Centre for Healthcare, and NIHR 
Collaborations for Leadership in Applied Health Research and Care.
Introduction 
Several procedures are available to investigate patients 
with symptoms suggestive of colorectal cancer. Barium 
enema (BE) is the most long-established method and, 
despite concerns about its sensitivity,1 ﬁ gures from the 
UK Department of Health show that more than 
70 000 BE examinations were undertaken in 2011 in 
England alone.2
Computed tomographic colonography (CTC), or 
virtual colonoscopy, is a relatively new radiological tech-
nique for imaging the large bowel. It has received much 
attention as a screening test3–6 and has also been recom-
mended for investigation of patients with symp toms 
suggestive of colorectal cancer.7–9 CTC is thought to have 
higher sensitivity than BE and studies have shown that 
patients prefer it to BE.10–12 However, no randomised 
trials have been undertaken to guide health policy on 
whether CTC should replace BE.
We have undertaken two pragmatic multicentre random-
ised trials: one comparing CTC with BE, and another 
comparing CTC with colonoscopy. We chose this approach 
because most clinicians do not regard BE and colonoscopy 
as comparable tests, so one trial with three-way random-
isation between the procedures would be impractical.
We report here results of the trial comparing CTC 
with BE for diagnosis of colorectal cancer or large 
(≥10 mm) polyps in symptomatic patients for whom the 
referring clinician preferred a radiological examination. 
The parallel trial comparing CTC with colonoscopy,13 
and our studies of patient acceptability14,15 and cost-
eﬀ ectiveness,16 are reported elsewhere.
Methods
Study design and participants
The design and rationale of this multicentre randomised 
trial have been published previously.17 The trial protocol 
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can be found online. Research nurses at 21 UK National 
Health Service (NHS) teaching and general hospitals 
recruited patients referred by their family doctor for 
investigation of symptoms suggestive of colorectal 
cancer. Patients were eligible if they were aged 55 years 
or older, were ﬁ t to undergo full bowel preparation, had 
no known genetic predisposition to cancer, had no 
history of inﬂ ammatory bowel disease, had not had a 
whole-colon examination in the past 6 months, and 
were not in active follow-up for previous colorectal 
cancer. We obtained demographic and baseline clinical 
data such as age, sex, and symptoms for all potentially 
eligible patients. The consulting clinician then decided 
in line with usual practice whether to investigate the 
patient using colonoscopy or BE (the default exam-
inations). We created two parallel trials and, within 
each, patients were randomly assigned to the default 
examination or CTC.17 No patients were enrolled in 
both trials.
We obtained ethical approval from the Northern and 
Yorkshire Multicentre Research Ethics Committee and 
from all participating hospitals. The trials were supervised 
by independent data monitoring and trial steering commit-
tees. All patients gave informed written consent.
Randomisation
We randomly allocated patients (2:1) to receive either BE or 
CTC. A statistician (RE) generated the randomisation 
codes at a remote site, and codes were kept concealed until 
interventions were assigned. RE was involved in the design 
of both the trial and its database, but had no involvement 
in data collection or interpretation. Randomisation was 
done centrally by computer random number generation, 
in blocks of six, stratiﬁ ed by centre and patient sex. Par-
ticipants and those administering the procedures were not 
masked to the assigned study intervention.
Procedures
Double-contrast BE was undertaken after full bowel 
preparation and administration of an intravenous 
spasmo lytic, with carbon dioxide or air for insuﬄ  ation. 
Digital ﬂ uoroscopic images of the double-contrasted 
colorectum were obtained to the caecum, supplemented 
by overcouch decubitus ﬁ lms. 
Methods for CTC were in accordance with the con-
temporary consensus on best practice,18 including full 
bowel preparation and gas insuﬄ  ation. Multidetector-
row scanners (minimum four rows) were used with a 
maximum detector collimation of 2·5 mm and a pitch 
that allowed abdominal coverage (40 cm) within one 
breath-hold (20 s). Prone and supine scans were 
recommended. Readers used two-dimensional (2D) and 
three-dimensional (3D) visualisation as needed, but a 
minimum requirement was a primary 2D analysis with 
volume or surface rendering for problem solving. The 
reading platform was decided according to local 
preference, as was use of intravenous contrast and faecal 
tagging. Computer-assisted detection was available.
82 practitioners (radiologists or fully-trained radio-
graphic technicians) interpreted the BE studies. All reports 
were either written or veriﬁ ed by a radiologist, except in 
one centre where dual reporting by senior radiographers 
was standard practice. 39 radiologists (including 35 from 
the parallel trial of CTC vs colon oscopy13) interpreted the 
CTC studies. All readers of CTC were familiar with 
interpreting the procedure, and those who had read fewer 
than 100 cases, or who desired additional training, attended 
a supple mentary 2 day course. The radiologists and radi-
ographers issued a report as usual and completed a case 
report form. Flexible sigmoidoscopy (FS) was undertaken 
before the randomised procedure in some hospitals. 
Details of these FS examinations were recorded, including 
any lesions seen.
Adverse events within 24 h of the randomised 
procedure were recorded on the case report form, or on a 
questionnaire completed by patients the following 
morning. Details of unplanned hospital admissions 
within 30 days were collected by manually searching 
hospitals’ patient administration systems.
Referrals for additional tests after the randomised 
procedure were made at the discretion of local clinicians, 
and research nurses collected the reports from these 
procedures. 
Outcomes
The primary outcome was the detection rate of colorectal 
cancer or large (≥10 mm) polyps, conﬁ rmed histologically 
when possible. Secondary outcomes were miss rates for 
8484 symptomatic patients assessed for eligibility
3838 entered CT colonography vs barium enema trial
2553 randomly assigned to barium enema
26 withdrew consent
1285 randomly assigned to CT colonography
2527 analysed
 2300 had barium enema
 227 did not have barium enema‡
1277 analysed
 1206 had CT colonography
 71 did not have CT colonography†
3036 excluded*
 2176 clinician decision
 834 patient decision
 26 unknown
8 withdrew consent
1610 entered CT colonography 
  vs colonoscopy trial13
Figure 1: Trial proﬁ le
*Reasons why patients were not randomised can be found in the appendix. †19 had an alternative whole-colon 
examination; 52 did not have a whole-colon examination. ‡85 had an alternative whole-colon examination; 
142 did not have a whole-colon examination. 
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colorectal cancer, referral rates for additional colonic 
investigation, extracolonic cancer diagnoses, all-cause 
mortality, and serious adverse events. We also analysed 
extracolonic ﬁ ndings at CTC.
Our deﬁ nition of colorectal cancer included all cancers 
with International Statistical Classiﬁ cation of Diseases and 
Related Health Problems, revision 10 (ICD-10) site codes 
C18–C20. Polyp size was deﬁ ned as the largest measure-
ment at endoscopy, histology, or surgery. Details of cancer 
diagnoses (colonic and extracolonic) and deaths in the trial 
cohort were obtained from the NHS Information Centre 
(NHSIC). A colorectal cancer was deﬁ ned as missed if 
it was identiﬁ ed through NHSIC as occurring within 
36 months of randomisation, but was not detected by the 
randomised procedure or mentioned in the patient’s 
discharge letter.
We deﬁ ned additional colonic investigation as any 
subsequent examination of the colon until diagnosis 
(usually histological conﬁ rmation of a cancer or polyp), or 
until a patient was referred back to their family doctor.
Extracolonic cancers included all reported primary 
malig nant neoplasms, excluding colorectal cancers (C18–
C20) and non-melanoma malignant neoplasms of the 
skin (C44).
A serious adverse event was deﬁ ned as any incident 
causing hospital admission, death, threat to life, or 
permanent impairment.19 An expert panel consisting of a 
radiologist, a gastroenterologist, and a colorectal surgeon 
reviewed reasons for unplanned hospital admissions and 
deaths within 30 days to decide whether any were 
attributable to a randomly assigned procedure (reviewers 
were masked to the assigned procedure). Panel members 
assessed cases independently and a consensus was 
reached when any disagreement arose.
Patients with extracolonic ﬁ ndings at CTC were followed 
up until either a diagnosis was given, the patient was put 
into regular surveillance, or a decision was made not to 
investigate further. The expert panel reviewed diagnoses 
resulting from extracolonic ﬁ ndings at CTC to establish 
whether these diagnoses could have explained patients’ 
presenting symptoms.
Statistical analysis
We estimated that a sample size of 3402 would give 80% 
power to detect a signiﬁ cant diﬀ erence in detection rates 
of colorectal cancer or large polyps at α=0·05 (two-tailed), 
assuming a diagnostic yield of 5% for BE and 7·5% for 
CTC, and with randomisation in a 2:1 ratio in favour of 
BE.17 The primary outcome was analysed both by inten-
tion to treat and in only those patients who had their 
randomised procedure (excluding lesions seen at 
previous FS). All secondary outcomes were analysed only 
in patients who had their randomised procedure, except 
for extracolonic cancers and overall mortality, which were 
analysed by intention to treat. The analysis of detection 
rates was per patient, using the most advanced colonic 
lesion diagnosed.
We analysed all extracolonic cancers diagnosed within 
36 months of randomisation, and calculated expected 
num bers by applying age-sex-speciﬁ c cancer incidence for 
the general population to our cohort, having adjusted for 
reported mortality.20 We compared incidence assuming a 
Poisson distribution.
Categorical outcomes were compared using Pearson’s 
χ² test or Fisher’s exact test, as appropriate. We calculated 
relative risks (RRs) or risk diﬀ erences with 95% CIs. We 
showed RRs for the primary outcome by age group 
(<65 years and ≥65 years) and sex using forest plots, and 
used tests of interaction (Mantel-Haenszel) to identify 
signiﬁ cant diﬀ erences. To check whether clustering by 
trial centre aﬀ ected results, we also analysed the primary 
outcome using random eﬀ ects logistic models allowing 
for heterogeneity in the outcome and intervention eﬀ ects 
by centre (odds ratios were compared).21 All tests were 
two-tailed with signiﬁ cance assigned at 5%. We analysed 
the data using Stata 10.1.
The trial is an International Standard Randomised 
Controlled Trial, number 95152621.
Role of the funding source
The primary funder (the National Institute for Health 
Research) stipulated a randomised controlled design, but 
Patients included in CT 
colonography vs barium 
enema trial
Comparison of included and excluded patients
CT 
colonography 
(n=1277)
Barium 
enema 
(n=2527)
Patients 
included in CT 
colonography vs 
barium enema 
trial (n=3804)
Excluded 
patients* 
(n=3036)
p value
Sex 0·0371
Male 490 (38%) 983 (39%) 1473 (39%) 1251 (41%)
Female 787 (62%) 1544 (61%) 2331 (61%) 1785 (59%)
Age (years) <0·0001
55–64 416 (33%) 826 (33%) 1242 (33%) 802 (26%)
65–74 494 (39%) 993 (39%) 1487 (39%) 1045 (34%)
75–84 330 (26%) 640 (25%) 970 (25%) 930 (31%)
≥85 37 (3%) 68 (3%) 105 (3%) 259 (9%)
Symptoms†
Change in bowel habit 975 (76%) 1910 (76%) 2885 (76%) 1926 (63%) <0·0001
Harder, less frequent 166 (13%) 321 (13%) 487 (13%) 297 (10%) ··
Looser, more frequent 535 (42%) 1007 (40%) 1542 (41%) 1049 (35%) ··
Variable frequency 113 (9%) 240 (9%) 353 (9%) 180 (6%) ··
Unspeciﬁ ed 161 (13%) 342 (14%) 503 (13%) 400 (13%) ··
Rectal bleeding 388 (30%) 767 (30%) 1155 (30%) 1169 (39%) <0·0001
Abdominal pain 406 (32%) 819 (32%) 1225 (32%) 574 (19%) <0·0001
Anaemia 153 (12%) 319 (13%) 472 (12%) 620 (20%) <0·0001
Weight loss 185 (14%) 331 (13%) 516 (14%) 500 (16%) 0·0008
Other symptoms 138 (11%) 289 (11%) 427 (11%) 585 (19%) <0·0001
Data are number (%) unless otherwise speciﬁ ed. *Patients excluded from both this trial and the parallel CT 
colonography versus colonoscopy trial. †Some patients reported more than one symptom.
Table 1: Characteristics of patients included in this trial versus excluded patients
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no funders or providers of equipment were involved in 
the collection, analysis, or interpretation of data, nor in 
the writing or submitting of the report. SH, KW, ED, 
IK-H, and WA had full access to the study data, whereas 
CvW, GY, RJL, and JW had access to subsets of the data. 
All authors take responsibility for the decision to submit 
for publication.
Results
Recruitment for both trials began in March, 2004, and was 
completed in December, 2007. Of 8484 potentially eligible 
patients, 3036 were not included because either they or 
their clinician declined consent (for speciﬁ c reasons, see 
appendix) and 1610 entered the accom pany ing CTC versus 
colonoscopy trial.13 Of the remaining 3838 patients who 
entered the CTC versus BE trial, 34 subsequently withdrew 
consent (26 [1·0%] in the BE group and eight [0·6%] in 
the CTC group), leaving 3804 for analysis (2527 assigned 
to BE and 1277 to CTC; ﬁ gure 1).
The median age of participants in this trial was 69 years 
(IQR 62–75) and 2331 (61%) were women. The most 
frequent presenting symptoms were change in bowel 
habit, abdominal pain, and rectal bleeding (table 1). 
Participants included in this trial were more likely to be 
female, younger, and to present with abdominal pain or a 
change in bowel habit than were excluded patients. They 
were less likely to present with rectal bleeding, anaemia, 
or weight loss (table 1).
A lower proportion of patients assigned to BE than to 
CTC had their assigned procedure (2300 [91·0%] of 
2527 vs 1206 [94·4%] of 1277; p=0·0002). Reasons why 
patients did not have the procedure are outlined in the 
appendix. Of those patients who did not have the 
assigned procedure, 85 (37%) of 227 in the BE group 
and 19 (27%) of 71 in the CTC group had an alternative 
whole-colon exam ination (ﬁ gure 1).
FS was undertaken before the scheduled randomised 
procedure in 199 (7·9%) patients in the BE group and 
89 (7·0%) in the CTC group (p=0·32). Having FS did not 
aﬀ ect whether the patient subsequently had their 
randomised procedure (263 [91·3%] of 288 patients with 
previous FS vs 3243 [92·2%] of 3516 patients without FS 
had their randomised procedure; p=0·58).
Of 2527 patients assigned to BE, 141 (5·6%) were 
diagnosed with colorectal cancer or a large polyp: 
119 (4·7%) at BE, 16 (0·6%) at previous FS, and six 
(0·2%) after an alternative procedure. By comparison, 
93 (7·3%) of 1277 patients assigned to CTC had colo rectal 
cancer or a large polyp diagnosed: 85 (6·7%) at CTC, six 
(0·5%) at previous FS, and two (0·2%) after an alternative 
procedure (see footnote to table 2 for histological 
diagnoses of cancers and large polyps). The detection 
rate of colorectal cancer or large polyps was signiﬁ cantly 
higher in the CTC group than in the BE group (RR 1·31, 
95% CI 1·01–1·68; p=0·0390; table 2), due mainly to a 
higher detection rate of large polyps (p=0·0098). 
Detection rates of colorectal cancer did not diﬀ er 
signiﬁ cantly between groups (p=0·66). Analysis of only 
patients who had their randomised procedure, with 
exclusion of lesions seen at previous FS, showed that 
colorectal cancer or large polyps were detected 
signiﬁ cantly more frequently in those who had CTC than 
in those who had BE (p=0·0243; table 2). Models 
controlling for cluster ing by trial centre showed no 
attenuation of eﬀ ect (data not shown).
Relative detection rates diﬀ ered signiﬁ cantly by age 
(p=0·0159): in younger patients (<65 years), the detection 
rate after CTC was double that for BE, whereas in older 
patients (≥65 years) the rates were similar (ﬁ gure 2). This 
diﬀ erence might have arisen because lesions in younger 
patients were smaller (<65 years, median size 25 mm 
[IQR 12–40]; ≥65 years, 30 mm [15–50]) and CTC was 
more sensitive than was BE for the detection of smaller 
lesions (data not shown). Relative detection rates did not 
diﬀ er between men and women (p=0·66; ﬁ gure 2).
A higher proportion of patients who had CTC under-
went additional colonic investigation than did those who 
had BE (23·5% vs 18·3%; p=0·0003; table 3), with higher 
rates of additional investigation for suspected cancers or 
polyps of 10 mm or larger (11·0% vs 7·5%; p=0·0005), or 
for suspected smaller polyps (7·2% vs 2·3%; p<0·0001). 
Conversely, a lower proportion of patients who had CTC 
underwent additional colonic investigation because of an 
inadequate examin ation or clinical un certainty than did 
those who had BE (5·2% vs 8·5%; p=0·0005; table 3).
In patients having additional investigation after the 
randomised procedure, a colorectal cancer or large polyp 
was diagnosed in a similar proportion of patients in 
the CTC and BE groups, both overall (29% vs 28%, 
respectively) and speciﬁ cally in patients having an 
additional procedure to investigate large or smaller 
lesions (table 4).
At least one previously unknown extracolonic ﬁ nding 
was reported in 673 (57·8%) of the 1164 patients who 
had CTC and did not have colorectal cancer diagnosed 
See Online for appendix
CT 
colonography
Barium enema Relative risk 
(95% CI)
p value
All patients, n 1277 2527
Colorectal cancer or polyp ≥10 mm 93 (7·3%) 141 (5·6%) 1·31 (1·01–1·68) 0·0390
Colorectal cancer 47* (3·7%) 86† (3·4%) 1·08 (0·76–1·53) 0·66
Polyp ≥10 mm 46‡ (3·6%) 55§ (2·2%) 1·66 (1·13–2·43) 0·0098
Patients who had their randomised 
procedure, n¶
1206 2300
Colorectal cancer or polyp ≥10 mm 85 (7·0%) 119 (5·2%) 1·36 (1·04–1·78) 0·0243
Colorectal cancer 42 (3·5%) 73 (3·2%) 1·10 (0·76–1·59) 0·63
Polyp ≥10 mm 43 (3·6%) 46 (2·0%) 1·78 (1·18–2·69) 0·0051
Data are number, or number (%), unless otherwise speciﬁ ed. Only the most advanced lesion per patient is presented. 
*45 adenocarcinomas and two cancers that were not histologically conﬁ rmed. †80 adenocarcinomas, one carcinoid 
tumour, and ﬁ ve cancers that were not histologically conﬁ rmed. ‡41 adenomas, one serrated adenoma, one 
hyperplastic polyp, and three polyps excised but not retrieved. §51 adenomas, two hyperplastic polyps, one juvenile 
polyp, and one polyp excised but not retrieved. ¶Excludes lesions detected previously by ﬂ exible sigmoidoscopy. 
Table 2: Detection rates of colorectal cancer and large polyps
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before discharge. A referral for additional in vestigation 
was made in 87 (7·5%) patients, leading to diagnosis of 
extracolonic malignancy in 13 (see appendix), aortic 
aneurysm of 5·5 cm diameter or larger (the recom-
mended threshold for surgical referral)22 in ﬁ ve, and 
aortic aneurysm of 3·0–5·4 cm (recommended for 
surveillance)22 in 20. Of 87 patients referred for additional 
pro cedures, 31 (36%) were given an extra colonic diag-
nosis that explained at least one of their present-
ing symptoms. A more detailed analysis will be pub-
lished elsewhere.16
We analysed the data in June, 2012, when registration 
was reported to be 97% complete for cancers diag nosed 
until December, 201023 (at which point all patients had 
been followed up for at least 36 months), and all deaths 
until December, 2011, had been registered.24 At the time 
of analysis (median follow-up for deaths 5·4 years, 
IQR 4·7–6·0), 400 (15·8%) patients assigned to BE and 
201 (15·7%) assigned to CTC had died (p=0·94).
During the 3 year follow-up, colorectal cancer was 
subsequently diagnosed in three patients who had 
undergone CTC and 12 who had undergone BE, giving a 
miss rate of 7% (three of 45) for patients who had CTC 
and 14% (12 of 85) for those who had BE (diﬀ erence −7, 
95% CI −18 to 3; p=0·21). BE had a miss rate of 10% 
(ﬁ ve of 48) for distal cancers (up to and including the 
sigmoid colon) and 19% (seven of 37) for proximal 
cancers. The number of missed cancers after CTC was 
too small to undertake separate analyses of proximal and 
distal cancers.
During the 3 year follow-up, 78 primary extracolonic 
cancers were diagnosed in the CTC group and 131 in the 
BE group (see appendix); incidence did not diﬀ er 
between groups (21·3 per 1000 person-years in the CTC 
group vs 18·0 per 1000 person-years in the BE group; 
incidence rate ratio [IRR] 1·18, 95% CI 0·89–1·57; 
p=0·24). In the ﬁ rst year, rates of primary extracolonic 
cancer diagnosis in the trial cohort were nearly twice as 
high as expected (IRR 1·88, 1·33–2·65; p=0·0002), but 
again rates did not diﬀ er signiﬁ cantly between the CTC 
and BE groups (IRR 0·84, 0·54–1·30; p=0·43). CTC 
detected 11 (39%) of 28 extracolonic cancers diagnosed 
during the ﬁ rst year, whereas BE detected four (6%) of 66.
Minor adverse eﬀ ects are reported elsewhere;14 we 
report more serious adverse events here. An unplanned 
hospital admission within 30 days occurred in 
25 patients after BE and 14 after CTC. The expert panel 
judged ﬁ ve admissions as possibly attributable to a 
randomised procedure. Four occurred after BE (one 
cardiac arrest, one abdominal pain, one rectal bleeding, 
and one collapse after procedure). Another patient had 
free gas seen in the abdomen during CTC and was 
admitted with a suspected perforation that was treated 
con servatively. Three patients died within 30 days of 
BE—at 5 days (cardiac failure), 25 days (liver failure), 
and 28 days (perforated viscus)—and one after CTC, at 
30 days (obstructive pulmonary disease).
Figure 2: Detection of colorectal cancer or large (≥10mm) polyps by sex and age group
Barium enema Relative risk (95% CI)CT colonography
Sex
Men
Women
χ21=0·189; p=0·66
49/490 (10·0%)
44/787 (5·6%)
79/983 (8·0%)
62/1544 (4·0%)
1·24 (0·89–1·75)
1·39 (0·96–2·03)
Age (years)
<65
≥65
χ21=5·815; p=0·0159
28/416 (6·7%)
65/861 (7·5%)
24/826 (2·9%)
117/1701 (6·9%)
All patients
p=0·0390
93/1277 (7·3%) 141/2527 (5·6%)
2·32 (1·36–3·94)
1·10 (0·82–1·47)
1·31 (1·01–1·68)
Favours CT colonographyFavours barium enema
1·3110·5 2 3 4
CT 
colonography 
(n=1206)
Barium 
enema 
(n=2300)
Relative risk 
(95% CI)
p value
All referrals for additional colonic investigation 283* (23·5%) 422† (18·3%) 1·28 (1·12–1·46) 0·0003
Colorectal cancer or polyp ≥10 mm suspected 133 (11·0%) 173 (7·5%) 1·47 (1·18–1·82) 0·0005
Colorectal cancer 68 (5·6%) 86 (3·7%) ·· ··
Polyp ≥10 mm 65 (5·4%) 87 (3·8%) ·· ··
Smaller polyp suspected 87 (7·2%) 54 (2·3%) 3·07 (2·20–4·28) <0·0001
8–9 mm 18 (1·5%) 18 (0·8%) ·· ··
6–7 mm 34 (2·8%) 12 (0·5%) ·· ··
≤5 mm 35 (2·9%) 24 (1·0%) ·· ··
Clinical uncertainty (no lesions seen) 63 (5·2%) 195 (8·5%) 0·62 (0·47–0·81) 0·0005
Inadequate examination 34 (2·8%) 116 (5·0%) ·· ··
Adequate examination 29 (2·4%) 79 (3·4%) ·· ··
Data are number (%) unless otherwise speciﬁ ed. *259 patients were referred to endoscopy, six to radiology, and 
18 directly to surgery. †368 patients were referred to endoscopy, 29 to radiology, and 25 directly to surgery.
Table 3: Additional colonic investigation in patients who had their randomised procedure, by reason 
for investigation
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Discussion
This is the ﬁ rst randomised trial comparing CTC and BE 
for diagnosis of colorectal cancer or large polyps in sympto-
matic patients (see panel). It is also the ﬁ rst trial to compare 
rates of additional colonic investigation when the two tests 
are used in normal clinical practice. Our results show that 
CTC detected signiﬁ cantly more cancers or large polyps 
than did BE, suggesting that it is more sensitive for 
detection of such lesions. However, rates of additional 
colonic investigation were higher after CTC than after BE, 
due to higher detection rates of both large and small polyps.
Consistent with its higher sensitivity, CTC missed 
fewer colorectal cancers than did BE (7% vs 14%). This 
diﬀ erence was not statistically signiﬁ cant, but the miss 
rate of BE in this trial is similar to rates reported in 
several clinical audits.1,25–27 No audit data are available for 
miss rates after CTC in routine clinical practice, although 
in the parallel trial of CTC versus colonoscopy,13 one of 
29 cancers was missed by CTC. In a recent meta-analysis 
of 25 studies (9223 patients) in which CTC was compared 
with colonoscopy, the relative sensitivity of CTC for 
colorectal cancer was 96% (95% CI 94–98).28
FS might have been undertaken before CTC and BE in 
some centres because some physicians believe that 
radiological tests are less sensitive in the distal colon and 
rectum than is endoscopy. However, our results and 
those of previous audits show that the miss rate for 
colorectal cancer after BE is no higher in the left than the 
right colon.1,25
We report that signiﬁ cantly more large polyps were 
detected with CTC than with BE (p=0·0098). We could 
not directly calculate the miss rate for large polyps 
because colonoscopy was not used as a reference standard 
and no polyp registry exists. However, in the only study29 
in which all participants had BE, CTC, and colonoscopy, 
per-patient sensitivity for lesions of 10 mm or larger was 
only 48% (95% CI 35–61) for BE and 59% (46–71) for CTC. 
A similarly low sensitivity of 55% (40–70) was reported in 
a study of 600 patients having CTC before clinically 
indicated colonoscopy.30 These ﬁ gures conﬂ ict with the 
results of two meta-analyses showing sensitivities for 
large polyps of 85% (95% CI 79–91)31 and 93% (73–98)5 for 
CTC. Studies using multidetector scanners, lower 
collimations, and a higher-than-average proportion of 3D 
reading tend to report higher sensitivities than studies 
that do not use these measures;31 individual variability in 
the skills of radiologists is also likely to play an important 
role.32–34 In our trial, recommended methods for CTC 
were based on the contemporary consensus on best 
practice,18 which still meets minimum standards.35,36 The 
radiol ogists had all interpreted CTC before, and those 
who had interpreted fewer than 100 cases were given 
additional training. Continued development of clinical 
guidelines and a system of formalised training and 
testing will be needed as CTC becomes more widely used, 
along with focused retraining when needed, which has 
been shown to substantially improve radiologists’ ability 
to identify lesions.37
In our trial, patients were referred for additional 
colonic investi gation more frequently after CTC than 
after BE because of higher detection rates of both large 
and small polyps in the CTC group. Patients with 
radiologically detected polyps smaller than 10 mm need 
to be carefully managed, since most small lesions have 
CT colonography Barium enema
Additional 
colonic 
procedure 
undertaken
Colorectal 
cancer 
detected
Polyp 
≥10 mm 
detected
Colorectal 
cancer or 
polyp ≥10 mm 
detected
Additional 
colonic 
procedure 
undertaken
Colorectal 
cancer 
detected
Polyp 
≥10 mm 
detected
Colorectal 
cancer or 
polyp ≥10 mm 
detected
All referrals for additional colonic 
investigation
283 40* 43 83* (29%) 422 73 46 119 (28%)
Colorectal cancer or polyp ≥10 mm suspected 133 39 35 74 (56%) 173 68 39 107 (62%)
Colorectal cancer 68 36 2 38 86 64 7 71
Polyp ≥10 mm 65 3 33 36 87 4 32 36
Smaller polyp suspected 87 1 8 9 (10%) 54 1 3 4 (7%)
8–9 mm 18 1 5 6 18 0 0 0
6–7 mm 34 0 2 2 12 0 0 0
≤5 mm 35 0 1 1† 24 1 3 4‡
Clinical uncertainty (no lesions seen) 63 0 0 0 195 4 4 8 (4%)
Inadequate examination 34 0 0 0 116 4 2 6
Adequate examination 29 0 0 0 79 0 2 2
Data are number, or number (%). Only the most advanced lesion per patient is presented. *Two further patients had inoperable colorectal cancer found at CT colonography, and a 
subsequent colonic procedure was not undertaken. †5 mm sigmoid colon polyp at CT colonography, and a 10 mm sessile caecal polyp at subsequent colonoscopy. ‡Of these four 
patients, the ﬁ rst had a 5 mm caecal polyp at barium enema, and a 40 mm sessile caecal polyp at subsequent colonoscopy; the second had a 5 mm proximal sigmoid colon polyp at 
barium enema, and a 15 mm sessile descending colon polyp at subsequent colonoscopy; the third had a 5 mm descending colon polyp at barium enema, and a 10 mm wide-stalked 
sigmoid colon polyp at subsequent colonoscopy; the fourth had a 5 mm rectal polyp at barium enema, and a 30 mm sigmoid colon cancer at subsequent colonoscopy. 
Table 4: Results of additional colonic investigation in patients who had their randomised procedure, by reason for investigation
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low malignant potential and are unlikely to cause 
symptoms. However, larger lesions (including one 
cancer) were conﬁ rmed in a third of patients referred 
after detection of polyps measuring 8–9 mm at CTC, 
indicating a possible beneﬁ t of lowering the referral 
threshold to 8 mm. We found a low yield of cancers and 
large polyps in patients referred after detec tion of smaller 
polyps at CTC. However, after detec tion of polyps that 
were 5 mm or smaller at BE, four large lesions (including 
one cancer) were identiﬁ ed, sug gest ing that it might be 
diﬃ  cult to measure the size of sessile lesions at BE.
A potential advantage of CTC is that patients can have 
colonoscopy on the same day to remove a lesion or take a 
biopsy sample. Colonoscopy cannot be undertaken on 
the same day as BE because of residual barium suspen-
sion; patients need to attend the clinic again and undergo 
a second bowel preparation. However, same-day colon-
oscopy is only possible if CTC ﬁ ndings are reviewed 
promptly and if endoscopy departments have adequate 
capacity. In this trial, only ﬁ ve patients had a follow-up 
endoscopy on the same day as CTC.
Evidence suggests that patients prefer CTC to BE.10–12 In 
this trial, patients who had BE reported lower satisfaction 
and greater physical discomfort during and after the 
procedure than patients who had CTC.14 BE is also more 
physically demanding because several patient positions 
are needed, whereas only two (usually prone and supine) 
are needed for CTC. This feature of CTC makes it more 
suitable than BE for frail elderly patients, who account 
for many of those with symptoms.
Patients regard detection of extracolonic lesions as an 
advantage of CTC.38 In this trial, 7·5% of patients who had 
CTC underwent further investigation as a result of an 
extracolonic ﬁ nding. In some cases the ﬁ nding was unlikely 
to have caused symptoms, but was nevertheless clinically 
important (eg, aortic aneurysm). Most patients, however, 
were diag nosed with minor abnormalities, unlikely to 
result in any serious health problems if left undetected.16 
We also note that CTC did not detect all extracolonic 
cancers that were likely to have caused symptoms, and time 
to diagnosis was not shorter than for patients randomly 
assigned to BE (appendix). This ﬁ nding might be due to 
patients having subsequent tests to investigate persistent 
symptoms, but needs further investigation.
The health economic analysis of the trial is reported 
in more detail elsewhere.16 The mean incremental cost for 
each additional colorectal cancer or large polyp detected by 
CTC was £4235 at 2010–11 prices, reﬂ ecting both the 
higher unit cost of CTC compared with BE and the cost of 
investigation and treatment of the detected colonic lesions. 
CTC is therefore more expensive than BE, but the 
additional cost might be justiﬁ ed if a mortality beneﬁ t can 
be shown. We extrapolated the number of life-years saved 
over 20 years by taking into account patient age, stage of 
cancer, and transition probabilities from the scientiﬁ c 
literature. CTC yielded 21 additional life-years per 
1000 patients, with an incremental cost per life-year gained 
of £2684 for CTC compared with BE. With discounting 
(3·5% per year as recommended by the National Institute 
for Health and Clinical Excellence [NICE]), the incremental 
cost per life-year saved was £3486, making it probable that 
CTC would fulﬁ l the NICE criteria for cost-eﬀ ectiveness.
Results of our study show that CTC is more sensitive 
than BE for detection of colorectal cancer or large polyps, 
and we have reported previously that CTC is preferred by 
patients.14 The higher sensitivity of CTC for small polyps 
and its ability to detect extracolonic lesions oﬀ er equivocal 
beneﬁ ts, since these incur additional costs and patients 
might be referred for investigation of ﬁ ndings that are 
clinically unimportant. However, this risk can be managed 
if more widespread use of CTC is accompanied by 
protocols for best practice, including guidelines on patient 
referral for both radiologists and referring clinicians. 
Training and quality assurance for radiologists are also 
needed if the capabilities of CTC are to be fully realised. 
With these provisos, our results suggest that CTC should 
now replace BE as the preferred radiological test for 
patients with symptoms suggestive of colorectal cancer.
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Panel: Research in context
Systematic review
We searched the Medline database for reports on CT colonography (CTC) published 
between 1994 and 2003, with the terms “colonography”, “colography”, “CT 
colonoscopy”, “CT pneumocolon”, “virtual colonoscopy”, and “virtual endoscopy”. We did 
not apply any language restrictions. Additional searches using the Cochrane controlled 
trials register, Embase, Science Citation Index, and manual searches of key journals did not 
reveal any additional studies. 24 studies that met selection criteria were included in a 
meta-analysis, which showed that CTC was highly sensitive for the detection of colorectal 
cancer. However, we found no randomised trials comparing CTC with barium enema (BE), 
which remains widely used.
Interpretation
Our study is the ﬁ rst randomised trial to compare CTC and BE for investigation of patients 
with symptoms suggestive of colorectal cancer. We report that CTC detects signiﬁ cantly 
more colorectal cancers or large polyps than does BE, and has a lower miss rate for 
colorectal cancer. CTC is a less burdensome procedure than BE, particularly for older 
patients, and studies have shown that patients prefer CTC to BE.10–12,14  Additionally, CTC 
oﬀ ers the possibility of referring patients for same-day colonoscopy, which is impossible 
after BE. Taken together, these ﬁ ndings suggest that CTC should replace BE in this patient 
group. We also concluded that CTC leads to more follow-up tests than does BE. More 
widespread implementation of CTC should therefore be accompanied by protocols to 
optimise the sensitivity and speciﬁ city of the procedure, guidelines on reporting and 
patient referral, adequate training, and a system of continuous audit.
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